Literature DB >> 10848694

Trends in prostate cancer incidence, mortality and survival in England and Wales 1971-1998.

A Majeed1, P Babb, J Jones, M Quinn.   

Abstract

OBJECTIVES: To examine trends in prostate cancer incidence and mortality in England and Wales between 1971 and 1998, using a newly developed and validated national cancer database and the national mortality database.
METHODS: Age-standardized incidence and death rates were calculated directly and trends in relative survival rates among men with prostate cancer registered during 1971-1990 were examined.
RESULTS: The annual number of new cases of prostate cancer registered in England and Wales increased by 179% between 1971 and 1993, from 6174 to 17 210. Directly age-standardized incidence rates increased by 104% between 1971 and 1993, from 29 to 59 per 100 000. The number of deaths from prostate cancer increased by 113% between 1971 and 1998, from 4027 to 8570. Directly age-standardized death rates increased by 49% between 1971 and 1995 and then decreased by 8% between 1995 and 1998, an overall increase of 38% (20 to 27 per 100 000) between 1971 and 1998. The relative survival rate for prostate cancer among men diagnosed during 1986-1990 was 77% at 1 year and 42% at 5 years, compared with 67% and 33%, respectively, for cases diagnosed during 1971-1975. The increase in survival rates was confined to men diagnosed with prostate cancer up to 1985 and no increase was seen for cases diagnosed after 1985.
CONCLUSIONS: Prostate cancer is becoming a growing burden on the health service. The explanation for the large increase in prostate cancer incidence and mortality is unclear and needs further investigation. The lack of any improvement in survival rates in cases diagnosed after 1985 is of concern, and suggests that the current management of prostate cancer in both primary and secondary care may need to be reviewed.

Entities:  

Mesh:

Year:  2000        PMID: 10848694     DOI: 10.1046/j.1464-410x.2000.00661.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  9 in total

1.  Screening for prostate cancer in the UK. Seems to be creeping in by the back door.

Authors:  J L Donovan; S J Frankel; D E Neal; F C Hamdy
Journal:  BMJ       Date:  2001-10-06

Review 2.  A review of phase III clinical trials of prostate cancer chemoprevention.

Authors:  J F Thorpe; S Jain; T H Marczylo; A J Gescher; W P Steward; J K Mellon
Journal:  Ann R Coll Surg Engl       Date:  2007-04       Impact factor: 1.891

Review 3.  Androgen-independent prostate cancer: potential role of androgen and ErbB receptor signal transduction crosstalk.

Authors:  Soha Salama El Sheikh; Jan Domin; Paul Abel; Gordon Stamp; El-Nasir Lalani
Journal:  Neoplasia       Date:  2003 Mar-Apr       Impact factor: 5.715

4.  Incidence trends of prostate cancer in East Anglia, before and during the era of PSA diagnostic testing.

Authors:  N Pashayan; J Powles; C Brown; S W Duffy
Journal:  Br J Cancer       Date:  2006-07-11       Impact factor: 7.640

5.  Cancer incidence increasing globally: The role of relaxed natural selection.

Authors:  Wenpeng You; Maciej Henneberg
Journal:  Evol Appl       Date:  2017-08-24       Impact factor: 5.183

6.  Prostate Cancer Incidence is Correlated to Total Meat Intake– a Cross-National Ecologic Analysis of 172 Countries

Authors:  Wenpeng You; Maciej Henneberg
Journal:  Asian Pac J Cancer Prev       Date:  2018-08-24

7.  Trends in non-metastatic prostate cancer management in the Northern and Yorkshire region of England, 2000-2006.

Authors:  L Fairley; M Baker; J Whiteway; W Cross; D Forman
Journal:  Br J Cancer       Date:  2009-11-10       Impact factor: 7.640

8.  Socioeconomic inequalities in cancer survival in Scotland 1986-2000.

Authors:  L G Shack; B Rachet; D H Brewster; M P Coleman
Journal:  Br J Cancer       Date:  2007-09-18       Impact factor: 7.640

9.  Greater family size is associated with less cancer risk: an ecological analysis of 178 countries.

Authors:  Wenpeng You; Frank J Rühli; Renata J Henneberg; Maciej Henneberg
Journal:  BMC Cancer       Date:  2018-09-26       Impact factor: 4.430

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.